Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multi-center, Phase II study of treatment of patients with
advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and
erlotinib or sorafenib alone.